Cantai Therapeutics is Co-Founded by Agent Capital and 82VS to Advance Next-Generation Bispecific Antibodies for Autoimmune Diseases

WALTHAM, Mass.–(BUSINESS WIRE)–Cantai Therapeutics (“Cantai”) today announced its formation and the completion of a seed financing co-led by Agent Capital and 82VS (the affiliated venture studio of Alloy Therapeutics) with additional participation from Tellus BioVentures. The proceeds will be used to develop drug candidates to treat autoimmune and inflammatory disorders by developing cytokine-targeting bispecific antibodies that meaningfully improve the status quo for the millions of patients
Click here to view original post